Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bermejo

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|April 11, 2001
Prognostic assessment of uncomplicated first myocardial infarction by exercise echocardiography and Tc-99m tetrofosmin gated SPECTJ Candell-Riera, J Llevadot, C Santana, et al.
Tumori|November 1, 1996
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI)A Ribas, J Bellmunt, J Albanell, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2012
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II studyE Alba, L Calvo, J Albanell, et al.
ESMO Open|January 21, 2021
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancerA Adam-Artigues, I Garrido-Cano, S Simón, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)E M Ciruelos, J Cortés, H Cortés-Funes, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 7, 2019
Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III projectMª D Torregrosa, M J Escudero, I Paredero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2019
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancerM Oliveira, C Saura, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyL Gianni, C S Huang, D Egle, et al.
ESMO Open|November 26, 2025
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib studyS Kuemmel, K H Jung, L Andrade, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|April 11, 2001
Prognostic assessment of uncomplicated first myocardial infarction by exercise echocardiography and Tc-99m tetrofosmin gated SPECTJ Candell-Riera, J Llevadot, C Santana, et al.
Tumori|November 1, 1996
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI)A Ribas, J Bellmunt, J Albanell, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2012
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II studyE Alba, L Calvo, J Albanell, et al.
ESMO Open|January 21, 2021
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancerA Adam-Artigues, I Garrido-Cano, S Simón, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)E M Ciruelos, J Cortés, H Cortés-Funes, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 7, 2019
Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III projectMª D Torregrosa, M J Escudero, I Paredero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2019
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancerM Oliveira, C Saura, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyL Gianni, C S Huang, D Egle, et al.
ESMO Open|November 26, 2025
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib studyS Kuemmel, K H Jung, L Andrade, et al.
Pageof 10